Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Personalis develops and sells advanced cancer genomic tests and services used by pharmaceutical companies for drug development and by physicians for clinical diagnostics. The company operates a single reportable segment focused on precision oncology applications.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $14.5 million | $25.7 million | $52.3 million | $67.8 million |
| Net Loss | $(21.7) million | $(39.1) million | $(57.5) million | $(64.9) million |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.64) | $(0.65) | $(1.19) |
| Cash and Cash Equivalents | $50.0 million | $91.4 million (Dec 31, 2024) | Short-term investments: $100.5 million (Sep 30, 2025) | |
| Total Liquidity (Cash + Investments) | $150.5 million | $185.0 million (Dec 31, 2024) | ||
| Working Capital | $138.2 million | $171.9 million (Dec 31, 2024) | Total Debt: $2.3 million (Sep 30, 2025) | |
| Accumulated Deficit | $(607.4) million | $(549.9) million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Q3 2025 revenue decreased 44% year-over-year to $14.5 million. This was driven by expected declines in revenue from Natera (Enterprise sales), the VA Million Veteran Program (Population sequencing), and a decrease in pharma tests and services.
- Improved Net Loss: Net loss narrowed significantly in Q3 2025 compared to Q3 2024. The prior year period included a non-cash loss of $26.0 million related to the change in fair value of Tempus Warrants, which was not present in the current quarter.
- Cost of Revenue: Decreased 26% in Q3 2025 primarily due to lower revenue levels and reduced sample processing volumes, though fixed overhead absorption was lower.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 14% in Q3 2025 due to expanded marketing programs for the NeXT Personal Dx test and related Tempus sales activities.
- Cash Flow: Net cash used in operating activities increased to $52.7 million for the nine months ended September 30, 2025, compared to $37.4 million in the prior year period, attributed to working capital needs and lower gross margins.
Guidance, Outlook, and Risks
- Outlook: Management anticipates current cash and investments ($150.5 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring net losses for the foreseeable future.
- Strategic Focus: Continued investment in the NeXT Personal Dx clinical diagnostic platform, with a focus on securing Medicare coverage for lung cancer and expanding indications (breast, colorectal). The company delivered 4,388 clinical tests in Q3, a 364% year-over-year increase.
- Key Risks:
- Customer Concentration: Significant reliance on a limited number of customers. Moderna accounted for 25% of YTD 2025 revenue. The company does not expect a long-term commercial relationship with Natera beyond 2025.
- Reimbursement: Success depends on obtaining Medicare and private insurance coverage for clinical tests. As of September 30, 2025, Medicare coverage for NeXT Personal Dx has not been received.
- Capital Requirements: Future funding may be required via equity or debt, which could result in dilution or restrictive covenants.
- Regulatory: Risks associated with FDA enforcement discretion regarding Laboratory Developed Tests (LDTs) and potential future requirements for premarket clearance.
Investor Verification Checklist
- Customer Concentration: Verify the stability of revenue from top customers (Moderna, VA MVP) and the timeline for replacing Natera revenue.
- Reimbursement Status: Monitor progress on Medicare coverage determinations for NeXT Personal Dx, specifically for lung cancer and other indications.
- Liquidity Runway: Assess the burn rate relative to the $150.5 million cash position to confirm the 12-month operational runway.
- Tempus Partnership: Review the impact of the Tempus commercialization agreement on clinical test volume growth and associated costs.
- Capital Expenditures: Verify planned capital expenditures ($7.0 million for 2025) against actual spending to ensure alignment with capacity expansion goals.